Table 1.
Patient characteristics of the included pSS patients (n = 41)
| Characteristics | Values |
|---|---|
| Age, years, mean (s.d.) | 50.4 (13.6) |
| Female, n (%) | 40 (97.6) |
| ACR-EULAR items, n (%) | |
| Anti-SSA antibodies | 37 (90.2) |
| FS ≥1, parotid gland | 25 (61.0) |
| UWSF ≤0.1 ml/mina | 27 (65.9) |
| Schirmer’s test ≤5 mm/5 min | 32 (78.0) |
| OSS ≥5a | 23 (56.1) |
| SGUS ≥15b | 25 (61.0) |
| Parotid histology | |
| FS, median (IQR) | 1.1 (0.4–2.3) |
| CD45+ infiltrate, %, median (IQR) | 5.3 (2.2–18.9) |
| Fat, %, median (IQR) | 37.9 (24.2–45.8) |
| Fibrosis, %, median (IQR) | 19.8 (6.8–26.1) |
| Presence of lymphoepithelial lesions, n (%) | 20 (48.8) |
| ≤70% IgA plasma cells, n (%) | 15 (36.6) |
| Presence of germinal centres, n (%) | 14 (34.1) |
| Parotid saliva (biopsy side), median (IQR) | |
| UPF, ml/min | 0.00 (0.00–0.03) |
| SPF, ml/min | 0.06 (0.02–0.11) |
| Parotid ultrasonography (biopsy side), median (IQR) | |
| PGUS total score (range 0–13) | 4.0 (2.0–7.5) |
| PGUS-homogeneity (range 0–3) | 1.0 (0.0–2.0) |
| PGUS-hypo (range 0–3) | 1.0 (1.0–3.0) |
| PGUS-hyper (range 0–3) | 1.0 (1.0–1.0) |
a
<5% missing data. bSGUS is not (yet) included in the ACR-EULAR criteria, but a score of ≥15 has been proposed.
OSS: ocular staining score.